Correlation Engine 2.0
Clear Search sequence regions

  • acid (3)
  • acyl (8)
  • aebsf (11)
  • blood (1)
  • donor (1)
  • human (4)
  • plasma (6)
  • sulfones (2)
  • treatment effect (1)
  • Sizes of these terms reflect their relevance to your search.

    We evaluated the effect of different concentrations of the esterase inhibitor, AEBSF, and acid treatment on acyl-ghrelin stability in human plasma samples subjected to a freeze/thaw cycle. Four plasma samples were collected from each donor and treated with the following concentrations of AEBSF: 2 mg/ml, 1 mg/ml, 0.6 mg/ml, and 0 mg/ml. For each plasma tube collected, half of the aliquots were treated with HCl and stored at -80°C before measuring acyl-ghrelin concentration using enzyme-linked immunosorbent assay (ELISA). Treatment with 1 mg/ml AEBSF + HCl resulted in significantly higher acyl-ghrelin levels compared to all other treatments except 2 mg/ml AEBSF + HCl or 0.6 mg/ml AEBSF + HCl. While all HCl-treated samples had higher acyl-ghrelin levels than their AEBSF-matched un-acidified samples, only samples treated with 1 mg/ml AEBSF significantly differed in acyl-ghrelin levels as a result of HCl treatment. Our results suggest the use of 1 mg/ml AEBSF with HCl for optimal acyl-ghrelin stability in human plasma samples subjected to a freeze/thaw cycle before assay. Given that 2 mg/ml and 0.6 mg/ml AEBSF + HCl did not significantly differ from 1 mg/ml AEBSF + HCl, our data suggest that the use of AEBSF with HCl more potently prevents de-acylation of ghrelin than either treatment alone.


    S L Deschaine, L Leggio. Understanding plasma treatment effect on human acyl-ghrelin concentrations. European review for medical and pharmacological sciences. 2020 Feb;24(3):1585-1589

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32096210

    View Full Text